Global Multiple Sclerosis Drugs Market Report 2024

Multiple Sclerosis Drugs Global Market Report 2024 – By Drug Class (Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Stores), By Route Of Administration (Oral Drugs, Parenteral Drugs) – Market Size, Trends, And Global Forecast 2024-2033

Starting Price : $5000.00 | Pages : 250 | Published : January 2024 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request Sample
Request For Discount
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Multiple Sclerosis Drugs Market

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Multiple Sclerosis Drugs Market Definition And Segments

Multiple Sclerosis drug refers to medications that are designed to stop the progression of disability and disease relapses. These medications are referred to as ‘disease-modifying treatment’. These drugs target a protein on the surface of immune cells and reduce the number of white blood cells to help prevent MS relapses. The white blood cells' propensity for nerve injury may be reduced by this impact.

The main drug classes of multiple sclerosis drugs is immunomodulators, immunosuppressants, interferons, and others. Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The various routes of administration include oral drugs and parenteral drugs that are distributed through hospital pharmacies, retail pharmacies, and online stores.

The multiple sclerosis drugs market covered in this report is segmented –

1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes

2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores

3) By Route Of Administration: Oral Drugs, Parenteral Drugs

The multiple sclerosis drugs market size has grown strongly in recent years. It will grow from $29.66 billion in 2023 to $31.5 billion in 2024 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of multiple sclerosis, unmet medical need, rising investments from pharmaceuticals, growing awareness of multiple sclerosis.

The multiple sclerosis drugs market size is expected to see strongly grown in the next few years. It will grow to $47.97 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing availability of clinical trials, targeted therapy, growing focus on preventive medicine, growing demand for biosimilars, expanding geographical reach, combination therapies. Major trends in the forecast period include immunomodulatory and immunomodulatory drugs, long-acting formulations, patient-centric care, drug innovation, oral and infusion therapies.

Government And Non-Government Support Fueling Growth Of Multiple Sclerosis Drugs Market

The growth of the multiple sclerosis drugs market is aided by support from the government as well as non-government organizations. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, the government of Alberta in partnership with the Department of Economic Development, Trade, and Tourism in Canada invested $1 million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada, and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of the multiple sclerosis drugs market.

Increasing Prevalence Of Multiple Sclerosis

The increasing prevalence of multiple sclerosis is expected to drive the growth of the multiple sclerosis drug market going forward. Multiple sclerosis (MS) is a chronic and often disabling autoimmune disease that affects the central nervous system (CNS). Multiple sclerosis drugs are pharmaceuticals designed to manage and treat the symptoms and progression of multiple sclerosis (MS). These drugs can help alleviate symptoms, reduce relapses, slow the disease's progression, and improve the quality of life for individuals living with MS. For instance, in May 2023, according to an article published by Pace Hospitals, an India-based hospital, there are about 2.8 million MS patients worldwide, i.e. 35.9 per 100,000 population. The annual incidence rate in 75 reporting countries stands at 2.1 cases per 100,000 individuals, with an average age of diagnosis at 32 years. It exhibits a higher prevalence among females compared to males. Therefore, the increasing prevalence of multiple sclerosis will continue to drive the growth of the multiple sclerosis drug market.

Major companies operating in the multiple sclerosis drugs market include Biogen Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Bayer HealthCare LLC, Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Acorda Therapeutics Inc., Actelion Pharmaceuticals Ltd., EMD Serono Inc., AbbVie Inc., Bayer Schering Pharma AG, CinnoVex, Rebif, Bristol-Myers Squibb Company, Johnson & Johnson, Mallinckrodt Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Mylan N.V., Opexa Therapeutics Inc., Receptos Inc., Synthon Pharmaceuticals Inc., TG Therapeutics Inc., Alexion Pharmaceuticals Inc., Alkermes PLC, Amgen Inc., Apitope Technology (Bristol) Ltd., Atara Biotherapeutics Inc., Celgene Corporation, Genzyme Corporation

High Drug Prices Constrain Growth Of Multiple Sclerosis Drugs Market

The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of the multiple sclerosis drugs market. MS is a cureless disease with a high chance of disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment. The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify their cost-effectiveness to their consumers. As reported by the Institute for Clinical and Economic Review (ICER), MS drugs cost roughly between $63,000 and $104,000 annually. For instance, after receiving criticism from the National Multiple Sclerosis Society on the high price of Vumerity, a drug to treat relapse MS, Biogen, and Alkermes had to reduce the prices of the drug to $88,000 per year to make it affordable to the patients. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market.

Increasing Focus On New Product Launches To Meet Growing Demand For MS Drugs

The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. Multiple sclerosis requires lifelong treatment, which increases the overall cost of treating a patient. To provide better and more effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, the FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) for the treatment of relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both drugs were launched as easy-to-consume oral drugs.

Innovative Products And Competitive Strategies In The Multiple Sclerosis Drug Market

Major companies operating in the multiple sclerosis drug market are introducing innovative products such as Aidaptus auto-injector platform to gain a competitive edge in the market. The Aidaptus auto-injector platform is engineered to simplify operations and offer a versatile solution for pharmaceutical and biotechnology firms engaged in the development of diverse drug formulations including multiple sclerosis, intended for subcutaneous delivery. For instance, in September 2021, Owen Mumford, a UK-based medical device manufacturer launched Aidaptus auto-injector platform that was created for the administration of a wide range of drugs and biologics that require subcutaneous delivery. Aidaptus is a dual-purpose auto-injector, powered by a two-step spring mechanism, capable of accommodating both 1mL and 2.25 mL prefilled glass syringes within a single base device due to its versatile design that is designed to treat multiple sclerosis and other diseases.

Bristol-Myers Squibb Acquired Celgene

Bristol-Myers Squibb, a pharmaceutical company based in the United States, paid $74 billion for Celgene. Through the acquisition, Bristol-Myers Squibb aims to increase its product portfolio by utilizing the existing products of Celgene along with its technical and pipeline support. Ozanimod is one of Celgene’s pipeline drugs for the treatment of relapsing multiple sclerosis. The drug is currently in phase III clinical trials to be approved by the FDA. Celgene is a pharmaceutical company based in the United States that develops and markets medicines for cancer and inflammatory diseases such as multiple sclerosis.

North America was the largest region in the global multiple sclerosis drug market in 2023. The Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the multiple sclerosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The multiple sclerosis drug market consists of sales of lemtrada, novantrone, ocrevus, and tysabri. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The multiple sclerosis drugs market research report is one of a series of new reports from The Business Research Company that provides multiple sclerosis drugs market statistics, including multiple sclerosis drugs industry global market size, regional shares, competitors with a multiple sclerosis drugs market share, detailed multiple sclerosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis drugs industry. This multiple sclerosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Multiple Sclerosis Drugs Market Report Scope
Report AttributeDetails
Market Size Value In 2024 $31.5 billion
Revenue Forecast In 2033 $47.97 billion
Growth Rate CAGR of 11.1% from 2024 to 2033
Base Year For Estimation 2023
Actual Estimates/Historical Data 2018-2023
Forecast Period 2024 - 2028 - 2033
Market Representation Revenue in USD Billion and CAGR from 2024 to 2033
Segments Covered 1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes
2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores
3) By Route Of Administration: Oral Drugs, Parenteral Drugs
Regional Scope Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Country Scope Australia; China; India; Indonesia; Japan; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; New Zealand; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; France; Germany; UK; Austria; Belgium; Denmark; Finland; Ireland; Italy; Netherlands; Norway; Portugal; Spain; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa
Key Companies Profiled Biogen Inc.; Novartis International AG; F. Hoffmann-La Roche Ltd.; Bayer HealthCare LLC; Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Teva Pharmaceutical Industries Ltd.; GlaxoSmithKline plc; Acorda Therapeutics Inc.; Actelion Pharmaceuticals Ltd; EMD Serono Inc.; AbbVie Inc.; Bayer Schering Pharma AG; CinnoVex; Rebif; Bristol-Myers Squibb Company; Johnson & Johnson; Mallinckrodt Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Mylan N.V.; Opexa Therapeutics Inc.; Receptos Inc.; Synthon Pharmaceuticals Inc.; TG Therapeutics Inc.; Alexion Pharmaceuticals Inc.; Alkermes plc; Amgen Inc.; Apitope Technology (Bristol) Ltd.; Atara Biotherapeutics Inc.; Celgene Corporation; Genzyme Corporation
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Multiple Sclerosis Drugs Market Characteristics

    3. Multiple Sclerosis Drugs Market Trends And Strategies

    4. Multiple Sclerosis Drugs Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On the Market

    4.2. Ukraine-Russia War Impact On the Market

    4.3. COVID-19 Impact On the Market

    5. Global Multiple Sclerosis Drugs Market Size and Growth

    5.1. Global Multiple Sclerosis Drugs Market Drivers and Restraints

    5.1.1. Drivers Of The Market

    5.1.2. Restraints Of The Market

    5.2. Global Multiple Sclerosis Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)

    5.3. Global Multiple Sclerosis Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

    6. Multiple Sclerosis Drugs Market Segmentation

    6.1. Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Immunomodulators

    Immunosuppressants

    Interferons

    Other Drug Classes

    6.2. Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Stores

    6.3. Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    Oral Drugs

    Parenteral Drugs

    7. Multiple Sclerosis Drugs Market Regional And Country Analysis

    7.1. Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    7.2. Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8. Asia-Pacific Multiple Sclerosis Drugs Market

    8.1. Asia-Pacific Multiple Sclerosis Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.3. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    8.4. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    9. China Multiple Sclerosis Drugs Market

    9.1. China Multiple Sclerosis Drugs Market Overview

    9.2. China Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.3. China Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    9.4. China Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

    10. India Multiple Sclerosis Drugs Market

    10.1. India Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.2. India Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    10.3. India Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11. Japan Multiple Sclerosis Drugs Market

    11.1. Japan Multiple Sclerosis Drugs Market Overview

    11.2. Japan Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.3. Japan Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    11.4. Japan Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12. Australia Multiple Sclerosis Drugs Market

    12.1. Australia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.2. Australia Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    12.3. Australia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13. Indonesia Multiple Sclerosis Drugs Market

    13.1. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.2. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    13.3. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14. South Korea Multiple Sclerosis Drugs Market

    14.1. South Korea Multiple Sclerosis Drugs Market Overview

    14.2. South Korea Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.3. South Korea Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    14.4. South Korea Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15. Western Europe Multiple Sclerosis Drugs Market

    15.1. Western Europe Multiple Sclerosis Drugs Market Overview

    15.2. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.3. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    15.4. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16. UK Multiple Sclerosis Drugs Market

    16.1. UK Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.2. UK Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    16.3. UK Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17. Germany Multiple Sclerosis Drugs Market

    17.1. Germany Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.2. Germany Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    17.3. Germany Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18. France Multiple Sclerosis Drugs Market

    18.5. France Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.6. France Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    18.7. France Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19. Italy Multiple Sclerosis Drugs Market

    19.9. Italy Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.10. Italy Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    19.11. Italy Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20. Spain Multiple Sclerosis Drugs Market

    20.13. Spain Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.14. Spain Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    20.15. Spain Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21. Eastern Europe Multiple Sclerosis Drugs Market

    21.1. Eastern Europe Multiple Sclerosis Drugs Market Overview

    21.2. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.3. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    21.4. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22. Russia Multiple Sclerosis Drugs Market

    22.1. Russia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.2. Russia Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    22.3. Russia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23. North America Multiple Sclerosis Drugs Market

    23.1. North America Multiple Sclerosis Drugs Market Overview

    23.2. North America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.3. North America Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    23.4. North America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24. USA Multiple Sclerosis Drugs Market

    24.1. USA Multiple Sclerosis Drugs Market Overview

    24.2. USA Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.3. USA Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    24.4. USA Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25. Canada Multiple Sclerosis Drugs Market

    25.1. Canada Multiple Sclerosis Drugs Market Overview

    25.2. Canada Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.3. Canada Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    25.4. Canada Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26. South America Multiple Sclerosis Drugs Market

    26.1. South America Multiple Sclerosis Drugs Market Overview

    26.2. South America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.3. South America Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    26.4. South America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27. Brazil Multiple Sclerosis Drugs Market

    27.1. Brazil Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.2. Brazil Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    27.3. Brazil Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28. Middle East Multiple Sclerosis Drugs Market

    28.1. Middle East Multiple Sclerosis Drugs Market Overview

    28.2. Middle East Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.3. Middle East Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    28.4. Middle East Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29. Africa Multiple Sclerosis Drugs Market

    29.1. Africa Multiple Sclerosis Drugs Market Overview

    29.2. Africa Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.3. Africa Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    29.4. Africa Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

    30. Multiple Sclerosis Drugs Market Competitive Landscape And Company Profiles

    30.1. Multiple Sclerosis Drugs Market Competitive Landscape

    30.2. Multiple Sclerosis Drugs Market Company Profiles

    30.2.1. Biogen Inc.

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Novartis International AG

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. F. Hoffmann-La Roche Ltd.

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Bayer HealthCare LLC

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Pfizer Inc

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Global Multiple Sclerosis Drugs Market Competitive Benchmarking

    32. Global Multiple Sclerosis Drugs Market Competitive Dashboard

    33. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market

    34. Multiple Sclerosis Drugs Market Future Outlook and Potential Analysis

    34.1 Multiple Sclerosis Drugs Market In 2028 - Countries Offering Most New Opportunities

    34.2 Multiple Sclerosis Drugs Market In 2028 - Segments Offering Most New Opportunities

    34.3 Multiple Sclerosis Drugs Market In 2028 - Growth Strategies

    34.3.1 Market Trend Based Strategies

    34.3.2 Competitor Strategies

    35. Appendix

    35.1. Abbreviations

    35.2. Currencies

    35.3. Historic And Forecast Inflation Rates

    35.4. Research Inquiries

    35.5. The Business Research Company

    35.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Table 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Table 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 10: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 11: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 12: China, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 13: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 14: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 15: India, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 16: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 17: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 18: Japan, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 19: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 20: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 21: Australia, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 22: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 23: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 24: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 25: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 26: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 27: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 28: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 29: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 30: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 31: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 32: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 33: UK, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 34: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 35: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 36: Germany, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 37: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 38: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 39: France, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 40: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 41: Italy, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 42: Italy, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 43: Italy, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 44: Spain, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 45: Spain, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 46: Spain, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 47: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 48: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 49: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 50: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 51: Russia, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 52: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 53: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 54: North America, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 55: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 56: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 57: USA, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 58: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 59: Canada, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 60: Canada, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 61: Canada, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 62: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 63: South America, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 64: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 65: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 66: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 67: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 68: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 69: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 70: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 71: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 72: Africa, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 73: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Table 74: Biogen Inc. Financial Performance
  • Table 75: Novartis International AG Financial Performance
  • Table 76: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 77: Bayer HealthCare LLC Financial Performance
  • Table 78: Pfizer Inc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2018-2023, $ Billion
  • Figure 2: Global Forecast Market Growth, 2023-2028F, 2033F, $ Billion
  • Figure 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 10: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 11: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 12: China, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 13: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 14: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 15: India, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 16: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 17: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 18: Japan, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 19: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 20: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 21: Australia, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 22: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 23: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 24: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 25: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 26: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 27: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 28: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 29: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 30: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 31: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 32: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 33: UK, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 34: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 35: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 36: Germany, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 37: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 38: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 39: France, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 40: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 41: Italy, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 42: Italy, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 43: Italy, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 44: Spain, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 45: Spain, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 46: Spain, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 47: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 48: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 49: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 50: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 51: Russia, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 52: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 53: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 54: North America, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 55: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 56: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 57: USA, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 58: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 59: Canada, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 60: Canada, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 61: Canada, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 62: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 63: South America, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 64: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 65: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 66: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 67: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 68: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 69: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 70: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 71: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 72: Africa, Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 73: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Figure 74: Biogen Inc. Financial Performance
  • Figure 75: Novartis International AG Financial Performance
  • Figure 76: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 77: Bayer HealthCare LLC Financial Performance
  • Figure 78: Pfizer Inc Financial Performance
Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company
Read More
Global Gene Therapy Market 2022 – Market Opportunities And Strategies
Read More
The Microbiome Market Share, Market Size, And Growth Rate 2022
Read More
Latest TNF Alpha Inhibitors Market Growth Study 2022-2026 By The Business Research Company
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
Read More
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
Read More
Neurology Devices Global Market Report 2024 – By Type (Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Device), By Type of Expenditure (Public, Private), By Product (Instruments/Equipment, Disposables), By End User (Hospitals And Clinics, Diagnostic Laboratories, Other End Users) – Market Size, Trends, And Global Forecast 2024-203
View Report
Interventional Neurology Devices And Equipment Global Market Report 2024 – By Type (Aneurysm Coiling & Embolization Devices, Cerebrospinal Fluid Management Devices, Neurothrombectomy Devices, Support Devices), Aneurysm Coiling & Embolization Devices By Type (Embolic coils, Flow diversion devices, Liquid embolic devices), Angioplasty Devices by Type (Carotid artery stents, Embolic protection systems), Support Devices By Type, Micro guide wires, Micro catheters), Neurothrombectomy Devices By Type (CLOT retrieval devices, Suction and aspiration devices, Snare), By End-User (Hospitals, Neurology clinics, Ambulatory care centers and others) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Neurosurgery Devices And Equipment Global Market Report 2024 – By Device Type (Neuroendoscope, Stereotactic Systems, Aneurysm Clips, Neurostimulation Devices, Cerebrospinal Fluid Management Devices, Neurosurgical Evacuation Device, Neurosurgical Navigation Systems, Neurosurgery Surgical Power Tools, Others (Ultrasonic Aspirators, Surgical Instruments)), By Surgery Type (Intracranial Surgery, Endonasal Neurosurgery, Spinal Surgery), By End User (Hospitals, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Brain And Neuroimaging Devices Global Market Report 2024 – By Imaging Type (Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG), Other Imaging Types), By Application (Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Other Applications), By End-user (Hospitals, Diagnostic Centres, Ambulatory Surgical Centres) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Neuroprosthetics Global Market Report 2024 – By Type (Motor Neuroprosthetics, Auditory Neuroprosthetics/ Cochlear implants, Visual Neuroprosthetics/ Retinal implants, Cognitive Neuroprosthetics ), By Technique (Spinal Cord Stimulation, Deep Brain Stimulation, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Transcranial Magnetic Stimulation ), By Application (Motor Neuron Disorders, Physiological Disorders, Cognitive Disorders ) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Macular Degeneration Treatment Global Market Report 2024 – By Stage of Disease (Early-Stage AMD, Intermediate AMD, Late-Stage AMD), By End User (Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals), By Route of Administration (Oral, Injectable, Other Route of Administration), By Types (Wet Macular Degeneration, Dry Macular Degeneration) – Market Size, Trends, And Global Forecast 2024-2033
View Report
Central Nervous System Drugs Global Market Report 2022 – By Type (Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
View Report

Frequently Asked Questions

What is the definition of the multiple sclerosis drugs market?

Multi sclerosis drug refers to medications that are designed to stop the progression of disability and disease relapses. These medications are referred to as "disease-modifying treatments." These drugs target a protein on the surface of immune cells and reduce the number of white blood cells to help prevent MS relapses. The white blood cells' propensity for nerve injury may be reduced by this impact. For further insights on the multiple sclerosis drugs market, request a sample here

How will the multiple sclerosis drugs market drivers and restraints affect the multiple sclerosis drugs market dynamics? What forces will shape the multiple sclerosis drugs industry going forward?

The multiple sclerosis drugs market growth is aided by the support from the government as well as non-government organizations. However, some multiple sclerosis drugs market restraints include high cost of drugs to treat multiple sclerosis (MS). For further insights on the multiple sclerosis drugs market, request a sample here

What is the forecast market size or the forecast market value of the multiple sclerosis drugs market?

The multiple sclerosis drugs market is expected to reach $37.67 billion in 2027 at a rate of 7.8%. For further insights on the multiple sclerosis drugs market, request a sample here

How is the multiple sclerosis drugs market segmented?

The global multiple sclerosis drugs market is segmented as
1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Other Drug Classes
2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores
3) By Route Of Administration: Oral Drugs, Parenteral Drugs
For further insights on the multiple sclerosis drugs market, request a sample here

Which region has the largest share of the multiple sclerosis drugs market? What are the largest region's market size and growth rate?

North America was the largest region in the multiple sclerosis drugs market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

Who are the major players in the multiple sclerosis drugs market?

Key competitors in the multiple sclerosis drugs market are, Biogen, Novartis, Roche, Bayer HealthCare, Pfizer Inc., Merck & Co. Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Acorda Therapeutics Inc., Actelion Pharmaceutical, EMD Serono, AbbVie Inc., Betaseron, CinnoVex, Extavia, Rebif, Tysabr. For further insights on the multiple sclerosis drugs market, request a sample here.

What are the key trends in the multiple sclerosis drugs market?

Major trends influencing the multiple sclerosis drugs market include rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. Multiple sclerosis requires lifelong treatment, which increases the overall cost of treating a patient. To provide better and more effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. For further insights on the multiple sclerosis drugs market, request a sample here.

What are the major opportunities in the multiple sclerosis drugs market? What are the strategies for the multiple sclerosis drugs market?

For detailed insights on the major opportunities and strategies in the multiple sclerosis drugs market, request a sample here.

How does the multiple sclerosis drugs market relate to the overall economy and other similar markets?

For detailed insights on multiple sclerosis drugs market's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the multiple sclerosis drugs industry?

For detailed insights on the mergers and acquisitions in the multiple sclerosis drugs industry, request a sample here.

What are the key dynamics influencing the multiple sclerosis drugs market growth? SWOT analysis of the multiple sclerosis drugs market.

For detailed insights on the key dynamics influencing the multiple sclerosis drugs market growth and SWOT analysis of the multiple sclerosis drugs industry, request a sample here.